Shots:

• Regeneron reported changes to the P-III study assessing REGEN-COV in non-hospitalized patients with COVID-19- following recommendations from the IDMC
• The IDMC found clear clinical efficacy in reducing the rate of hospitalization and death with both doses (1-200 & 2-400 mg) of REGEN-COV vs PBO. The company will immediately stop enrolling patients in the PBO group- following the IDMC’s recommendation
• The trial will continue to enroll patients in both treatment arms. IDMC has also reassured that REGEN-COV effectively neutralizes emerging strains of the virus in its preclinical data

 ­ Ref: Regeneron | Image: The Print